Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) gapped down prior to trading on Friday following insider selling activity. The stock had previously closed at $22.45, but opened at $21.50. IGM Biosciences shares last traded at $21.55, with a volume of 576 shares trading hands. Specifically, Director Michael D. Loberg purchased 5,821 shares of the company’s stock in a transaction that occurred on Thursday, September 29th. The shares were bought at an average cost of $19.62 per share, with a total value of $114,208.02. Following the completion of the transaction, the director now directly owns 35,305 shares of the company’s stock, valued at $692,684.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Michael D. Loberg purchased 5,821 shares of the company’s stock in a transaction that occurred on Thursday, September 29th. The shares were bought at an average cost of $19.62 per share, with a total value of $114,208.02. Following the completion of the transaction, the director now directly owns 35,305 shares of the company’s stock, valued at $692,684.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bruce Keyt sold 8,700 shares of the firm’s stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $22.82, for a total transaction of $198,534.00. Following the transaction, the insider now directly owns 39,489 shares in the company, valued at $901,138.98. The disclosure for this sale can be found here. Insiders sold 55,000 shares of company stock worth $1,193,107 over the last three months. 55.96% of the stock is currently owned by insiders.

Analyst Ratings Changes

IGMS has been the topic of several research reports. Guggenheim lowered their price objective on shares of IGM Biosciences to $40.00 in a research report on Monday, August 15th. Bank of America initiated coverage on shares of IGM Biosciences in a research report on Monday, August 29th. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, Truist Financial lowered their price objective on shares of IGM Biosciences from $74.00 to $37.00 and set a “buy” rating on the stock in a research report on Tuesday, August 23rd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

IGM Biosciences Price Performance

The firm’s 50-day moving average price is $20.80 and its 200-day moving average price is $19.12.

IGM Biosciences (NASDAQ:IGMS – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported ($1.33) EPS for the quarter, beating the consensus estimate of ($1.44) by $0.11. The firm had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $38.91 million. During the same period in the prior year, the firm posted ($1.16) EPS. On average, sell-side analysts expect that IGM Biosciences, Inc. will post -5.86 EPS for the current year.

Hedge Funds Weigh In On IGM Biosciences

Hedge funds have recently bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new position in IGM Biosciences during the fourth quarter valued at approximately $34,000. Walleye Capital LLC purchased a new stake in shares of IGM Biosciences during the 4th quarter valued at $1,030,000. Swiss National Bank raised its position in shares of IGM Biosciences by 16.2% during the 2nd quarter. Swiss National Bank now owns 21,500 shares of the company’s stock valued at $388,000 after buying an additional 3,000 shares in the last quarter. Alpha Paradigm Partners LLC purchased a new stake in shares of IGM Biosciences during the 2nd quarter valued at $161,000. Finally, Virtus ETF Advisers LLC raised its position in shares of IGM Biosciences by 32.9% during the 2nd quarter. Virtus ETF Advisers LLC now owns 7,267 shares of the company’s stock valued at $131,000 after buying an additional 1,798 shares in the last quarter. Hedge funds and other institutional investors own 41.20% of the company’s stock.

IGM Biosciences Company Profile

(Get Rating)

IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company’s lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL).

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider IGM Biosciences, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and IGM Biosciences wasn’t on the list.

While IGM Biosciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here